CNS Drugs

, Volume 22, Issue 5, pp 367–388 | Cite as

Aripiprazole in the Treatment of Depressive and Anxiety Disorders

A Review of Current Evidence
  • Chi-Un Pae
  • Alessandro Serretti
  • Ashwin A. Patkar
  • Praksh S. Masand
Review Article


Despite the availability of different classes of drugs for the treatment of depressive and anxiety disorders, there are a number of clinically significant unmet needs, such as a high prevalence of treatment resistance, partial response, subsyndromal symptomatology, recurrence and relapse. With the approval of atypical antipsychotics, which are associated with a lower adverse effect burden than typical antipsychotics, consideration of their off-label use for the treatment of affective disorders and various other psychiatric disorders has become a viable option. However, consideration should be given to the US FDA black box warning indicating that atypical antipsychotics may increase mortality risk, particularly in the elderly population with dementia-related psychosis.

There has been much conjecture about the utility of these atypical drugs to facilitate traditional antidepressant therapy, either in combination (from the initiation of therapy) or as adjunctive therapy (in the case of partial/incomplete response). Nevertheless, at present, available evidence from randomized, placebo-controlled trials is sparse, and a formal risk/benefit assessment of the use of these agents in a nonpsychotic patient population is not yet possible.

As a representative agent from the atypical antipsychotic class with a novel mechanism of action and a relatively low adverse effect burden, aripiprazole represents an interesting potential treatment for depressive and anxiety disorders. In this review, we focus on the rationale for the use of aripiprazole in these disorders.

Preclinical data suggests that aripiprazole has a number of possible mechanisms of action that may be important in the treatment of depressive and anxiety disorders. Such mechanisms include aripiprazole action at serotonin (5-HT) receptors as a 5-HT1a partial receptor agonist, a 5-HT2C partial receptor agonist and a 5-HT2a receptor antagonist. Aripiprazole also acts as a dopamine D2 partial receptor agonist, and has a possible action at adrenergic receptors. Furthermore, aripiprazole may have possible neuroprotective effects.

Clinical studies demonstrate that aripiprazole may be useful in the treatment of bipolar depression, major depressive disorder, treatment-resistant depression and possibly anxiety disorders. Clinical data also suggest that aripiprazole may have a lower adverse effect burden than the other atypical drugs.

Future research may confirm the potential utility of aripiprazole in the treatment of depressive and anxiety disorders.



The authors received no financial support to prepare this review and have no conflicts of interest directly relevant to its contents.

Dr Pae has received research grants from the Korean divisions of GlaxoSmithKline, AstraZeneca, Janssen Pharmaceuticals, Eli Lilly and Company, Otsuka, Wyeth Pharmaceuticals, the Korean Research Foundation and the Korean Institute of Science and Technology Evaluation and Planning; and has received honoraria and is on the speaker’s bureaus of the Korean divisions of GlaxoSmithKline, Lundbeck, AstraZeneca, Janssen Pharmaceuticals, Eli Lilly and Company, McNeil Consumer and Specialty Inc. and Otsuka.

Dr Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser; is on the speaker’s bureau of Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser; and has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc., Organon, Jazz Pharmaceuticals and Pfizer Inc.

Dr Masand is a consultant for Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline, i3CME, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer Inc., Targacept Inc. and Wyeth Pharmaceuticals; is on the speaker’s bureau of AstraZeneca, Bristol-Myers Squibb Company, Forest laboratories Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., and Wyeth Pharmaceuticals; and has received research support from AstraZeneca, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, Forest laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceuticals and Wyeth Pharmaceuticals.


  1. 1.
    Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002; 63(11): 963–71PubMedCrossRefGoogle Scholar
  2. 2.
    Dilsaver SC, Swann AC, Shoaib AM, et al. Depressive mania associated with nonresponse to antimanic agents. Am J Psychiatry 1993; 150(10): 1548–51PubMedGoogle Scholar
  3. 3.
    Grunze H. Reevaluating therapies for bipolar depression. J Clin Psychiatry 2005; 66Suppl. 5: 17–25PubMedGoogle Scholar
  4. 4.
    Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006; 11(9): 805–14PubMedCrossRefGoogle Scholar
  5. 5.
    Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996; 153(10): 1293–300PubMedGoogle Scholar
  6. 6.
    Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157 (4 Suppl.): 1–45Google Scholar
  7. 7.
    Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19(6): 567–96PubMedCrossRefGoogle Scholar
  8. 8.
    Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003; 166(4): 391–9Google Scholar
  9. 9.
    McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65Suppl. 18: 47–56PubMedGoogle Scholar
  10. 10.
    Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60(7): 681–90PubMedCrossRefGoogle Scholar
  11. 11.
    Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44(2): 179–87PubMedCrossRefGoogle Scholar
  12. 12.
    Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9): 763–71PubMedCrossRefGoogle Scholar
  13. 13.
    Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61(2–3): 123–36PubMedCrossRefGoogle Scholar
  14. 14.
    Bristol-Myers Squibb. Abilify®: prescribing information [online]. Available from URL: [Accessed 2007 May 1]
  15. 15.
    Green B. Focus on aripiprazole. Curr Med Res Opin 2004; 20(2): 207–13PubMedCrossRefGoogle Scholar
  16. 16.
    Swainston-Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64(15): 1715–36PubMedCrossRefGoogle Scholar
  17. 17.
    Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18(4): 251–67PubMedCrossRefGoogle Scholar
  18. 18.
    Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441(3): 137–40PubMedCrossRefGoogle Scholar
  19. 19.
    Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28(8): 1400–11PubMedCrossRefGoogle Scholar
  20. 20.
    Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190(3): 373–82CrossRefGoogle Scholar
  21. 21.
    Kikuchi T, Tottori K, Uwahodo Y, et al. 7- (4-[4- (2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2 (1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274(1): 329–36PubMedGoogle Scholar
  22. 22.
    Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005; 7(6): 268–74PubMedCrossRefGoogle Scholar
  23. 23.
    DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26(5): 649–66CrossRefGoogle Scholar
  24. 24.
    Matsubara K, Shimizu K, Suno M, et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 2006; 1112(1): 126–33PubMedCrossRefGoogle Scholar
  25. 25.
    Yoshino T, Nisijima K, Katoh S, et al. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT (1A) receptors in the rat medial frontal cortex. Neurochem Int 2002; 40(4): 355–60PubMedCrossRefGoogle Scholar
  26. 26.
    Assie MB, Ravailhe V, Faucillon V, et al. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005; 315(1): 265–72PubMedCrossRefGoogle Scholar
  27. 27.
    De Vry J, Schreiber R, Melon C, et al. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressantlike effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 2004; 14(6): 487–95PubMedCrossRefGoogle Scholar
  28. 28.
    Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry 2003; 53(3): 193–203PubMedCrossRefGoogle Scholar
  29. 29.
    Gobert A, Rivet JM, Cistarelli JM, et al. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 1997; 68(3): 1326–9PubMedCrossRefGoogle Scholar
  30. 30.
    Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493(1–3): 75–83PubMedCrossRefGoogle Scholar
  31. 31.
    Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT (2A) and D (2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76(5): 1521–31PubMedCrossRefGoogle Scholar
  32. 32.
    Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005; 387(3): 157–61PubMedCrossRefGoogle Scholar
  33. 33.
    Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59(12): 664–8PubMedCrossRefGoogle Scholar
  34. 34.
    Jenkins SW, Robinson DS, Fabre Jr LF, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990; 10(3): 77–85SCrossRefGoogle Scholar
  35. 35.
    Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999; 45(9): 1170–7PubMedCrossRefGoogle Scholar
  36. 36.
    Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006; 7(2): 139–47PubMedCrossRefGoogle Scholar
  37. 37.
    Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301(5634): 805–9PubMedCrossRefGoogle Scholar
  38. 38.
    Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006; 26(2): 157–62PubMedCrossRefGoogle Scholar
  39. 39.
    Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66Suppl. 5: 40–8PubMedGoogle Scholar
  40. 40.
    Overstreet DH, Knapp DJ, Angel RA, et al. Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology (Berl) 2006; 187(1): 1–12CrossRefGoogle Scholar
  41. 41.
    Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3): CD006115Google Scholar
  42. 42.
    Giorgetti M, Tecott LH. Contributions of 5-HT (2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004; 488(1–3): 1–9PubMedCrossRefGoogle Scholar
  43. 43.
    Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 1997; 94(5): 2036–40PubMedCrossRefGoogle Scholar
  44. 44.
    Gurevich I, Tamir H, Arango V, et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002; 34(3): 349–56PubMedCrossRefGoogle Scholar
  45. 45.
    Dremencov E, Newman ME, Kinor N, et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005; 48(1): 34–42PubMedCrossRefGoogle Scholar
  46. 46.
    Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19(4): 467–89PubMedCrossRefGoogle Scholar
  47. 47.
    Martin JR, Bos M, Jenck F, et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998; 286(2): 913–24PubMedGoogle Scholar
  48. 48.
    Moreau JL, Bos M, Jenck F, et al. 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 1996; 6(3): 169–75PubMedCrossRefGoogle Scholar
  49. 49.
    Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(7): 1159–72PubMedCrossRefGoogle Scholar
  50. 50.
    Massou JM, Trichard C, Attar-Levy D, et al. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl) 1997; 133(1): 99–101CrossRefGoogle Scholar
  51. 51.
    Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002; 161(3): 263–70CrossRefGoogle Scholar
  52. 52.
    Moran-Gates T, Massari C, Graulich A, et al. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res 2006; 84(3): 675–82PubMedCrossRefGoogle Scholar
  53. 53.
    Marek GJ, Martin-Ruiz R, Abo A, et al. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacol 2005; 30(12): 2205–15CrossRefGoogle Scholar
  54. 54.
    Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000; 33(6): 236–8PubMedCrossRefGoogle Scholar
  55. 55.
    Szabo ST, Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT (2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 2002; 302(3): 983–91PubMedCrossRefGoogle Scholar
  56. 56.
    Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 1998; 51: 219–44PubMedCrossRefGoogle Scholar
  57. 57.
    Schmuck K, Ullmer C, Kalkman HO, et al. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996; 8(5): 959–67PubMedCrossRefGoogle Scholar
  58. 58.
    Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch Pharmacol 1994; 350(3): 225–9PubMedCrossRefGoogle Scholar
  59. 59.
    Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 2005; 8(1): 93–105PubMedCrossRefGoogle Scholar
  60. 60.
    Hamel E. The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 1999; 26Suppl. 3: S2–6PubMedGoogle Scholar
  61. 61.
    Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005; 108(3): 320–33PubMedCrossRefGoogle Scholar
  62. 62.
    Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 2005; 48(4): 492–502PubMedCrossRefGoogle Scholar
  63. 63.
    Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12Suppl. 3: S7–14PubMedCrossRefGoogle Scholar
  64. 64.
    Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66(1): 85–93PubMedCrossRefGoogle Scholar
  65. 65.
    Wada T, Kanno M, Aoshima T, et al. Dose-dependent augmentation effect of bromocriptine in a case with refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(2): 457–62PubMedCrossRefGoogle Scholar
  66. 66.
    Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4(5): 307–14PubMedCrossRefGoogle Scholar
  67. 67.
    Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol 1999; 20(6): 612–27CrossRefGoogle Scholar
  68. 68.
    Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483(1): 45–53PubMedCrossRefGoogle Scholar
  69. 69.
    Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86(1): 37–45PubMedCrossRefGoogle Scholar
  70. 70.
    Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) 1994; 115(4): 441–6CrossRefGoogle Scholar
  71. 71.
    Moresco RM, Colombo C, Fazio F, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage 2000; 12(4): 452–65PubMedCrossRefGoogle Scholar
  72. 72.
    Bowden C, Theodorou AE, Cheetham SC, et al. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 1997; 752(1–2): 227–33PubMedCrossRefGoogle Scholar
  73. 73.
    Zhang JY, Kowal DM, Nawoschik SP, et al. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006; 71(4): 521–9PubMedCrossRefGoogle Scholar
  74. 74.
    Amargos-Bosch M, Artigas F, Adell A. Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 2005; 516(3): 235–8PubMedCrossRefGoogle Scholar
  75. 75.
    Dawe GS, Huff KD, Vandergriff JL, et al. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 2001; 50(7): 510–20PubMedCrossRefGoogle Scholar
  76. 76.
    Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 2004; 504(1–2): 61–4PubMedCrossRefGoogle Scholar
  77. 77.
    Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007; 98(1–2): 143–51PubMedCrossRefGoogle Scholar
  78. 78.
    McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005; 10(6): 525–37PubMedCrossRefGoogle Scholar
  79. 79.
    Cosi C, Waget A, Rollet K, et al. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 2005; 1043(1–2): 32–41PubMedCrossRefGoogle Scholar
  80. 80.
    Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63(8): 856–64PubMedCrossRefGoogle Scholar
  81. 81.
    Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47(4): 351–4PubMedCrossRefGoogle Scholar
  82. 82.
    Zarate Jr CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163(1): 153–5PubMedCrossRefGoogle Scholar
  83. 83.
    Shelton RC. Olanzapine/fluoxetine combination for bipolar depression. Expert Rev Neurother 2006; 6(1): 33–9PubMedCrossRefGoogle Scholar
  84. 84.
    Post RM, Calabrese JR. Bipolar depression: the role of atypical antipsychotics. Expert Rev Neurother 2004; 4(6 Suppl. 2): S27–33PubMedCrossRefGoogle Scholar
  85. 85.
    Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20(4): 536–46PubMedCrossRefGoogle Scholar
  86. 86.
    Keck Jr PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67(4): 626–37PubMedCrossRefGoogle Scholar
  87. 87.
    Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160(9): 1651–8PubMedCrossRefGoogle Scholar
  88. 88.
    Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235–42Google Scholar
  89. 89.
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278–96PubMedCrossRefGoogle Scholar
  90. 90.
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–76PubMedCrossRefGoogle Scholar
  91. 91.
    Ketter TA, Wang PW, Chandler RA, et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006; 18(3): 169–72PubMedCrossRefGoogle Scholar
  92. 92.
    Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): National Institute of Mental Health, 1976. DHEW pub. no. (ADM) 76-338Google Scholar
  93. 93.
    Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53(11): 1028–42PubMedCrossRefGoogle Scholar
  94. 94.
    Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 574–7PubMedCrossRefGoogle Scholar
  95. 95.
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRefGoogle Scholar
  96. 96.
    Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65(7): 975–81PubMedCrossRefGoogle Scholar
  97. 97.
    Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24(4): 365–73PubMedCrossRefGoogle Scholar
  98. 98.
    Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/ fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66(10): 1289–97PubMedCrossRefGoogle Scholar
  99. 99.
    Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158(1): 131–4PubMedCrossRefGoogle Scholar
  100. 100.
    Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31(11): 2505–13PubMedCrossRefGoogle Scholar
  101. 101.
    Dunner D, Amsterdam JD, Shelton RC, et al. Adjunctive ziprasidone for resistant depression: 8-week pilot study [abstract]. Eur Neuropsychopharmacol 2005; 15Suppl. 3: 444Google Scholar
  102. 102.
    Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16(4): 189–94PubMedCrossRefGoogle Scholar
  103. 103.
    Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66(10): 1216–20PubMedCrossRefGoogle Scholar
  104. 104.
    Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8(2): 82–7PubMedCrossRefGoogle Scholar
  105. 105.
    Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007; 24(7): 522–6PubMedCrossRefGoogle Scholar
  106. 106.
    Worthington III JJ, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20(1): 9–11PubMedCrossRefGoogle Scholar
  107. 107.
    Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66(10): 1326–30PubMedCrossRefGoogle Scholar
  108. 108.
    Berman RM, Marcus R, Swanink R, et al. Efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (study CN138–139) [poster no. 310]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)Google Scholar
  109. 109.
    Kim D, Berman RM, Marcus R, et al. Aripiprazole as adjunctive therapy in major depressive disorder with and without chronic features (CN138–139) [poster no. 283]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19–24; San Diego (CA)Google Scholar
  110. 110. (a service of the US National Institutes of Health [online]. Available from URL: [Accessed 2007 May 1]
  111. 111.
    Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005; 66(1): 49–51PubMedCrossRefGoogle Scholar
  112. 112.
    Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005; 86(1): 99–104PubMedCrossRefGoogle Scholar
  113. 113.
    Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163(5): 833–8PubMedCrossRefGoogle Scholar
  114. 114.
    Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46(11): 1006–11Google Scholar
  115. 115.
    Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale: II. Validity. Arch Gen Psychiatry 1989; 46(11): 1012–6CrossRefGoogle Scholar
  116. 116.
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50–5PubMedCrossRefGoogle Scholar
  117. 117.
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361–70PubMedCrossRefGoogle Scholar
  118. 118.
    Sheehan D. The anxiety disease. New York: Charles Scribner’s Sons, 1983Google Scholar
  119. 119.
    Franke G. SCL-90-R: Symptom-checkliste von LR Derogatis. Goettingen: Beltz, 2002Google Scholar
  120. 120.
    Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67(9): 1327–40PubMedCrossRefGoogle Scholar
  121. 121.
    El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006; (2): CD004578Google Scholar
  122. 122.
    Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988; 145(11): 1455–6PubMedGoogle Scholar
  123. 123.
    BMS. Aripiprazole: prescribing information [online]. Available from URL: [Accessed 2007 Mar 22]
  124. 124.
    Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100(1): 4–22PubMedCrossRefGoogle Scholar
  125. 125.
    Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 2005; 162(2): 397–8PubMedCrossRefGoogle Scholar
  126. 126.
    Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotics. Am J Psychiatry 2002; 159(4): 672–3PubMedCrossRefGoogle Scholar
  127. 127.
    Hamilton S, Malone K. Serotonin syndrome during treatment with paroxetine and risperidone. J Clin Psychopharmacol 2000; 20(1): 103–5PubMedCrossRefGoogle Scholar
  128. 128.
    Aripiprazole: new drug. Just another neuroleptic. Prescrire Int 2005; 14(79): 163–7Google Scholar
  129. 129.
    Keck Jr PE, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl. 4: 33–8PubMedGoogle Scholar
  130. 130.
    Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6(4): 325–37PubMedCrossRefGoogle Scholar
  131. 131.
    Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naive patient. J Clin Psychopharmacol 2006; 26(1): 94–5PubMedCrossRefGoogle Scholar
  132. 132.
    Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006; 11(6): 435–9PubMedGoogle Scholar
  133. 133.
    Grant MJ, Baldessarini RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005; 39(11): 1953PubMedGoogle Scholar
  134. 134.
    Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28(6): 744–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Chi-Un Pae
    • 1
    • 2
  • Alessandro Serretti
    • 3
  • Ashwin A. Patkar
    • 2
  • Praksh S. Masand
    • 2
  1. 1.Department of Psychiatry, Kangnam St Mary’s HospitalThe Catholic University of Korea College of MedicineSeoulSouth Korea
  2. 2.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA
  3. 3.Institute of PsychiatryUniversity of BolognaBolognaItaly

Personalised recommendations